Posted by Michael Wonder on 28 Nov 2022
Lantheus announces the approval of Definity (perflutren lipid microsphere) by China’s NMPA
28 November 2022 - Definity is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms.
Lantheus today announced that the Center for Drug Evaluation of China’s NMPA has approved the import drug license for perflutren lipid microsphere injectable suspension (marketed as Definity in the US), the Company’s diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms.
